Adjusted EBITDA margin improved by 500 basis points to 8.4%, compared to 3.4% in Q2 2024, reflecting operational efficiencies and volume leverage.
Adjusted net loss improved to $10.2 million or $0.32 per share from $18.8 million or $0.61 per share in Q2 2024.
Adjusted operating expenses increased 16% year-over-year to $145.2 million due to remediation activities, global volume growth support, and investments in innovation and commercial initiatives.
Expanded access to Zio services as an in-network benefit to over 10 million additional patients in the U.S.
Gross margin was 71.2%, ahead of expectations, benefiting from volume leverage and operational efficiencies despite higher costs from increased Zio AT mix.
iRhythm reported Q2 2025 revenue of $186.7 million, up 26.1% year-over-year, driven by growth in core long-term continuous monitoring and Zio AT product lines.
New store growth accounted for approximately 68% of year-over-year volume growth, with home enrollment for Zio Services at about 23% of volume in the U.S.
Cash burn for the quarter was approximately $11 million, a 36% improvement over the same period last year, ending with a cash position of $222 million.
ClonoSEQ test volumes increased 37% year-over-year to 25,321 tests delivered.
MRD business achieved positive adjusted EBITDA of $1.9 million, a significant improvement from a $11.3 million deficit a year ago.
MRD business revenue grew 42% year-over-year to $49.9 million, with clinical and pharma contributions of 65% and 35%, respectively.
Net loss for the quarter was $25.6 million.
Sequencing gross margin improved by 14 percentage points year-over-year to 64%.
Total company adjusted EBITDA loss improved to $7.2 million from a $21.4 million loss in the prior year.
Total revenue for Q2 2025 was $58.9 million, a 36% increase year-over-year.
Cash from operations increased by approximately $47 million in the first half of 2025, with a clean balance sheet and strong cash conversion dynamics.
Gross margin improved to 63.4% in Q2 2025 compared to approximately 59% in Q2 2024, with steady sequential margins excluding true-ups despite increased exome volumes.
Natera reported $547 million in revenue for Q2 2025, representing 32% growth year-over-year and 34% growth excluding revenue true-ups.
Non-cash stock-based compensation and legal accruals of about $30 million impacted EPS, with adjusted EPS loss estimated at $0.53 versus reported $0.74.
Operating expenses are expected to remain flat for 2025 despite increased investments, reflecting scale in the business.
Dafinchi